ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Holdings Boosted by Great West Life Assurance Co. Can

Great West Life Assurance Co. Can grew its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 8.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,614 shares of the specialty pharmaceutical company’s stock after buying an additional 1,000 shares during the period. Great West Life Assurance Co. Can owned 0.11% of ANI Pharmaceuticals worth $590,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in ANIP. Vanguard Group Inc. lifted its holdings in shares of ANI Pharmaceuticals by 5.7% in the 1st quarter. Vanguard Group Inc. now owns 441,226 shares of the specialty pharmaceutical company’s stock valued at $21,845,000 after purchasing an additional 23,806 shares during the last quarter. Renaissance Technologies LLC increased its position in ANI Pharmaceuticals by 19.5% in the 1st quarter. Renaissance Technologies LLC now owns 278,000 shares of the specialty pharmaceutical company’s stock valued at $13,764,000 after acquiring an additional 45,300 shares during the period. Nomura Holdings Inc. increased its position in ANI Pharmaceuticals by 0.6% in the 1st quarter. Nomura Holdings Inc. now owns 208,901 shares of the specialty pharmaceutical company’s stock valued at $10,352,000 after acquiring an additional 1,164 shares during the period. Bank of America Corp DE increased its position in ANI Pharmaceuticals by 25.5% in the 1st quarter. Bank of America Corp DE now owns 197,224 shares of the specialty pharmaceutical company’s stock valued at $9,764,000 after acquiring an additional 40,111 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in ANI Pharmaceuticals by 94.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 177,525 shares of the specialty pharmaceutical company’s stock valued at $8,789,000 after acquiring an additional 86,011 shares during the period. 55.86% of the stock is owned by institutional investors.

WARNING: “ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Holdings Boosted by Great West Life Assurance Co. Can” was originally published by BBNS and is the sole property of of BBNS. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://baseballnewssource.com/markets/great-west-life-assurance-co-can-has-590000-holdings-in-ani-pharmaceuticals-inc-anip/1608864.html.

Shares of ANI Pharmaceuticals, Inc. (NASDAQ ANIP) traded down 1.73% during midday trading on Friday, hitting $50.04. The stock had a trading volume of 57,902 shares. The firm has a 50 day moving average of $46.79 and a 200-day moving average of $47.75. The company has a market cap of $582.37 million, a P/E ratio of 109.50 and a beta of 3.10. ANI Pharmaceuticals, Inc. has a one year low of $42.23 and a one year high of $69.85.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.19. The firm had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $43.20 million. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. The company’s revenue for the quarter was up 43.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.11 earnings per share. On average, analysts forecast that ANI Pharmaceuticals, Inc. will post $3.84 earnings per share for the current fiscal year.

Several research firms have issued reports on ANIP. Zacks Investment Research upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Guggenheim reiterated a “buy” rating and set a $80.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, July 4th. Canaccord Genuity began coverage on ANI Pharmaceuticals in a research report on Monday, July 31st. They set a “buy” rating and a $60.00 target price on the stock. BidaskClub cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Finally, ValuEngine cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $65.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

American League Once Again Dominates National League
American League Once Again Dominates National League
Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22


Leave a Reply

 
© 2006-2017 BBNS.